Pfizer’s Pentavalent Meningococcal Vaccine Candidate Shows Efficacy In Adolescents
Pfizer Inc (NYSE:PFE) has announced topline results from the Phase 3 trial of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy…
Sorrento Reports Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept; Says Achieving Improvements In Rheumatoid Arthritis Disease Measures At 50% Of Standard Dose For Patients (7 of 7) With Inadequate Response To Subcuta
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements
Processa Pharmaceuticals Provides Update On Enrollment Across All Clinical Programs
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is expected before year
Celsion Completes Enrollment Of The Phase I/II OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone
LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion
HeartBeam Granted Patent For 12-Lead Electrocardiogram (ECG) Patch Monitor Intended For Detection Of Heart Attacks And Complex Cardiac Arrhythmias
HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead
Top Financial Media Stories Thursday, September 15: US Railway Companies, Unions Reach Tentative Agreement, Tesla To Wind Down Stores In China’s Flashy Malls, Netflix Could Face Legal Action Over South Korean Crime Drama And More..
US Railway Companies, Unions Reach Tentative Agreement Averting Catastrophic Strike
Jasper Therapeutics Announces FDA Fast Track Designation For JSP191
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi
Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
Qurient Announces Collaboration Agreement With MSD To Evaluate Selective CDK7 Inhibitor Q901 In Combination With KEYTRUDA
https://www.businesswire.com/news/home/20220914005974/en/
Eloxx Shares Plummet As Mid-Stage Cystic Fibrosis Study Results Miss Efficacy Endpoints
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.